At pharmacologically relevant concentrations intravenous iron preparations cause pancreatic beta cell death

American Journal of Translational Research

Volumn 6, Issue 1, 2014, Pages 64-70

  Masuda, Yuichi ^a   Ichii, Hirohito ^a   Vaziri, Nosratola D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anemia; Cardiovascular disease; Chronic kidney disease; Diabetes; Glucose metabolism; Hemodialysis; Insulin; Metabolic syndrome

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; IRON; IRON SACCHARATE; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BLOOD VOLUME; CELL DEATH; CELL VIABILITY; CLINICAL ASSESSMENT; CONFOCAL MICROSCOPY; DRUG EXPOSURE; ELECTRON MICROSCOPY; FLUORESCENCE ACTIVATED CELL SORTING; INSULIN SYNTHESIS; MALE; NECROSIS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; RAT;

EID: 84889675405     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Swaminathan S, Fonseca VA, Alam MG, Shah SV. The role of iron in diabetes and its complications. Diabetes Care 2007; 30: 1926-1933.
2. Tuomainen TP, Nyyssonen K, Tervahauta A, Korpela H, Lakka T, Kaplan GA, Salonen JT. Body iron stores are associated with serum insulin and blood glucose concentrations - Population study of 1,013 eastern Finnish men. Diabetes Care 1997; 20: 426-428.
3. Lee DH, Folsom AR, Jacobs DR. Dietary iron intake and Type 2 diabetes incidence in postmenopausal women: the Iowa Women's Health Study. Diabetologia 2004; 47: 185-194.
4. Rajpathak S, Ma J, Manson J, Willett WC, Hu FB. Iron intake and the risk of type 2 diabetes in women - A prospective cohort study. Diabetes Care 2006; 29: 1370-1376.
5. Jehn M, Clark JM, Guallar E. Serum ferritin and risk of the metabolic syndrome in U.S adults. Diabetes Care 2004; 27: 2422-2428.
6. Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G, Tenuti I, Lotto V, Friso S, Pizzolo F, Corrocher R. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care 2005; 28: 2061-2063.
7. Lao TT, Tam KF. Maternal serum ferritin and gestational impaired glucose tolerance. Diabetes Care 1997; 20: 1368-1369.
8. Chen XH, Scholl TO, Stein TP. Association of elevated serum ferritin levels and the risk of gestational diabetes mellitus in pregnant women - The Camden study. Diabetes Care 2006; 29: 1077-1082.
9. Jiang R, Manson JE, Meigs JB, Ma J, Rifai N, Hu FB. Body iron stores in relation to risk of type 2 diabetes in apparently healthy women. JAMA 2004; 291: 711-717.
10. Fernandez-Real JM, Penarroja G, Castro A, Garcia-Bragado F, Hernandez-Aguado D, Ricart W. Bloodletting in high-ferritin type 2 diabetes - Effects on insulin sensitivity and beta-cell function. Diabetes 2002; 51: 1000-1004.
11. Bofill C, Joven J, Bages J, Vilella E, Sans T, Cavalle P, Miralles R, Llobet J, Camps J. Response to repeated phlebotomies in patients with non-insulin dependent diabetes mellitus. Metabolism 1994; 43: 614-620.
12. Lao TT, Ho LF. Impact of iron deficiency anemia on prevalence of gestational diabetes mellitus. Diabetes Care 2004; 27: 650-656.
13. Tiedge M, Lortz S, Drinkgern J, Lenzen S. Relation between antioxidant enzyme gene expression and antioxidative defense status of insulin-producing cells. Diabetes 1997; 46: 1733-1742.
14. Andrews NC. The iron transporter DMT1. Int J Biochem Cell Biol 1999; 31: 991-994.
15. Vaziri ND. Epidemic of Iron Overload in Dialysis Population Caused by Intravenous Iron Products: A Plea for Moderation. Am J Med 2012; 125: 951-952.
16. Canavese C, Bergamo D, Ciccone G, Longo F, Fop F, Thea A, Martina G, Piga A. Validation of serum ferritin values by magnetic susceptometry in predicting iron overload in dialysis patients. Kidney Int 2004; 65: 1091-1098.
17. Ferrari P, Kulkarni H, Dheda S, Betti S, Harrison C, St Pierre TG, Olynyk JK. Serum Iron Markers Are Inadequate for Guiding Iron Repletion in Chronic Kidney Disease. Clin J Am Soc Nephrol 2011; 6: 77-83.
18. Rostoker G, Griuncelli M, Loridon C, Couprie R, Benmaadi A, Bounhiol C, Roy M, Machado G, Janklewicz P, Drahi G, Dahan H, Cohen Y. Hemodialysis-associated Hemosiderosis in the Era of Erythropoiesis-stimulating Agents: A MRI Study. Am J Med 2012; 125: 991.
19. Van Campenhout A, Van Campenhout C, Lagrou A, Manuel-y-Keenoy B. Iron-induced oxidative stress in haemodialysis patients: a pilot study on the impact of diabetes. Biometals 2008; 21: 159-170.
20. Kuo KL, Hung SC, Wei YH, Tarng DC. Intravenous iron exacerbates oxidative DNA damage in peripheral blood lymphocytes in chronic hemodialysis patients. J Am Soc Nephrol 2008; 19: 1817-1826.
21. Garcia-Fernandez N, Echeverria A, Sanchez-Ibarrola A, Antonio Paramo J, Coma-Canella I. Randomized clinical trial on acute effects of i.v. iron sucrose during haemodialysis. Nephrology 2010; 15: 178-183.
22. Kamanna VS, Ganji SH, Shelkovnikov S, Norris K, Vaziri ND. Iron Sucrose Promotes Endothelial Injury and Dysfunction and Monocyte Adhesion/Infiltration. Am J Nephrol 2012; 35: 114-119.
23. Lim CS, Vaziri ND. The effects of iron dextran on the oxidative stress in cardiovascular tissues of rats with chronic renal failure. Kidney Int 2004; 65: 1802-1809.
24. Zhou XJ, Laszik Z, Wang XQ, Silva FG, Vaziri ND. Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest 2000; 80: 1905-1914.
25. Carlini RG, Alonzo E, Bellorin-Font E, Weisinger JR. Apoptotic stress pathway activation mediated by iron on endothelial cells in vitro. Nephrol Dial Transplant 2006; 21: 3055-3061.
26. Rooyakkers TM, Stroes ESG, Kooistra MP, van Faassen EE, Hider RC, Rabelink TJ, Marx JJM. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002; 32: 9-16.
27. Ichii H, Masuda Y, Hassanzadeh T, Saffarian M, Gollapudi S, Vaziri ND. Iron Sucrose Impairs Phagocytic Function and Promotes Apoptosis in Polymorphonuclear Leukocytes. Am J Nephrol 2012; 36: 50-57.
28. Deicher R, Ziai F, Cohen G, Mullner M, Horl WH. High-dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003; 64: 728-736.
29. Gupta A, Zhuo J, Zha J, Reddy S, Olp J, Pai A. Effect of different intravenous iron preparations on lymphocyte intracellular reactive oxygen species generation and subpopulation survival. BMC Nephrol 2010; 11: 16.
30. Shapiro AMJ, Hao E, Rajotte RV, Kneteman NM. High yield of rodent islets with intraductal collagenase and stationary digestion - A comparison with standard technique. Cell Transplant 1996; 5: 631-638.
31. Gotoh M, Maki T, Kiyoizumi T, Satomi S, Monaco AP. An improved method for isolation of mouse pancreatic islets. Transplantation 1985; 40: 437-438.
32. Ricordi C, eds. Pancreatic Islet Cell Transplantation. Austin: R.G. Lands Company; 1992.
33. Ricordi C, eds. Methods in Cell Transplantation. Austin: R.G. Landes Company; 1995.
34. Ichii H, Inverardi L, Pileggi A, Molano RD, Cabrera O, Caicedo A, Messinger S, Kuroda Y, Berggren PO, Ricordi C. A novel method for the assessment of cellular composition and beta-cell viability in human islet preparations. Am J Transplant 2005; 5: 1635-1645.
35. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients. Diabetologia 2002; 45: 85-96.
36. Lee YA, Cho EJ, Yokozawa T. Protective effect of persimmon (Diospyros kaki) peel proanthocyanidin against oxidative damage under H2O2-induced cellular senescence. Biol Pharm Bull 2008; 31: 1265-1269.
37. Ishida-Oku M, Iwase M, Sugitani A, Masutani K, Kitada H, Tanaka M, Iida M. Histologic Studies of Islets of Langerhans in Transplanted Pancreata from Marginal Donors in Japan. Transplant Proc 2010; 42: 1819-1821.
38. Kulaksiz H, Fein E, Redecker P, Stremmel W, Adler G, Cetin Y. Pancreatic beta-cells express hepcidin, an iron-uptake regulatory peptide. J Endocrinol 2008; 197: 241-249.
39. Qian MW, Liu M, Eaton JW. Transition metals bind to glycated proteins forming redox active "glycochelates": Implications for the pathogenesis of certain diabetic complications. Biochem Biophys Res Commun 1998; 250: 385-389.
40. Shah SV, Baliga R, Rajapurkar M, Fonseca VA. Oxidants in chronic kidney disease. J Am Soc Nephrol 2007; 18: 16-28.
41. Vaziri ND. Understanding iron: promoting its safe use in patients with chronic kidney failure treated by hemodialysis. Am J Kidney Dis 2013; 61: 992-1000.
42. Hoerl WH. Clinical aspects of iron use in the anemia of kidney disease. J Am Soc Nephrol 2007; 18: 382-393.